Cerner Enviza, John Snow Labs to support FDA’s drug safety initiative
Cerner Enviza, a company of Oracle, together with healthcare AI company John Snow Labs, is set to support the US Food and Drug Administration’s drug safety initiative, Sentinel.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XCerner Enviza, a company of Oracle, together with healthcare AI company John Snow Labs, is set to support the US Food and Drug Administration’s drug safety initiative, Sentinel.
Japanese pharmaceutical companies KinoPharma and IWAKI SEIYAKU have jointly launched a Phase 2 clinical trial to confirm the efficacy of a drug candidate in treating cutaneous warts. Cutaneous
Austria-based biotechnology firm Proxygen has signed a multi-year research collaboration and license agreement with Merck & Co, also known as MSD outside the US and Canada, to jointly
Canadian biopharmaceutical company Arbutus Biopharma together with its licensee Genevant Sciences has filed a patent infringement lawsuit against Pfizer and BioNTech. The companies filed the lawsuit with the
BioNTech has signed an exclusive license and collaboration agreement with China-based Duality Biologics (DualityBio) to develop two antibody-drug conjugate (ADC) assets. DualityBio is a clinical-stage biotech company focused
Sartorius, through its French unit Sartorius Stedim Biotech, has signed an agreement to acquire biotechnology company Polyplus for a total consideration of about €2.4bn. The French life science
British drugmaker GSK has signed an exclusive agreement with US-based biotechnology company Scynexis to license the latter’s antifungal therapy Brexafemme (ibrexafungerp tablets). Brexafemme is a novel oral glucan
Australian asset manager HMC Capital has signed an agreement with US-based healthcare investor Medical Properties Trust to acquire certain private hospitals in Australia for a total of A$1.20bn
Novartis and UK-based Bicycle Therapeutics have entered into a strategic collaboration to develop, manufacture and market bicyclic peptide (Bicycle) radio-conjugates (BRCs) for multiple oncology targets, mutually agreed by
Teva Pharmaceuticals announced that California’s Desert Oasis Healthcare (DOHC) system has implemented a respiratory patient monitoring programme based on its Digihaler System. The company designed the programme in